Volpara Solutions Inc. recently showcased its new Volpara Enterprise DDP software at the AHRA’s 45th Annual Meeting and Exposition. The VolparaEnterprise Clinical Applications software package offers access to VolparaDensity, VolparaDose, and VolparaPressure, in a software as a service (SaaS) subscription model for the first time.

The company also featured its entire suite of quantitative breast imaging tools, which allow for personalized measurements of volumetric breast density, patient dose, breast compression, and other factors designed to help maintain accuracy and consistent quality in breast screening.

 VolparaEnterprise Clinical Applications provide quick, automated assessment of every mammography and tomosynthesis exam and produces a Volpara Scorecard for every patient. The volumetric Volpara Density Grades have been shown to correlate strongly to the sensitivity of mammography and have demonstrated a strong association with the risk of developing breast cancer. Furthermore, VolparaDose helps understand the X-ray dose delivered to the patient, based on her specific breast density. Unlike manufacturer dose, which is based on phantom measurements, VolparaDose is computed based on the patient’s breast composition and provides a personalized dose measure because no two women are alike.
Meanwhile, VolparaPressure helps evaluate the effectiveness of the mammogram and to better understand the patient experience.  It helps monitor and optimize pressure during mammography exams, which is important to decrease the discomfort experienced by women and to optimize screening outcomes.

VolparaEnterprise software, a Microsoft Azure-based solution, delivers key performance indicators for hundreds of performance and quality metrics, including patient positioning, compression and equipment utilization. The software provides continuous quality assurance and performance monitoring through dynamic, interactive dashboards.  Updated with every mammography or tomosynthesis (3D mammography) exam, ConstantQuality metrics may help facilities comply with the FDA’s new EQUIP inspection program.

“VolparaEnterprise software has seamlessly integrated with VolparaDensity to offer users a robust clinical management resource to optimize productivity, quality assurance, and cancer detection rates,” says Ralph Highnam, PhD, Volpara chief scientist and CEO.  “Leveraging this Microsoft Azure-based enterprise platform has led to a natural transition for VolparaDensity and our other clinical tools to a Software as a Service subscription model.  We believe this will not only increase access to these critical breast imaging tools, but also expand their clinical utility.”